source
- Roivant reports record-breaking Phase 2 results for PH-ILD drug mosliciguat, starts Phase 3Roivant announced that its experimental drug mosliciguat met all primary and secondary endpoints in a Phase 2 study in patients with pulmonary hypertension associated with interstitial lung disease…
- FDA approves AstraZeneca's new breast cancer therapyThe U.S. Food and Drug Administration has granted approval for AstraZeneca's latest breast cancer drug, expanding treatment options for patients with the disease. The approval follows a review of…